DGAP-News: MeVis Medical Solutions AG: MeVis gains first industrial customer for lung screening software

        Print
| Source: EQS Group AG
DGAP-News: MeVis Medical Solutions AG / Key word(s): Product Launch
MeVis Medical Solutions AG: MeVis gains first industrial customer for
lung screening software

14.08.2014 / 17:45

---------------------------------------------------------------------

Industrial customer uses MeVis' software for early entry into growth market
of lung cancer screening

  - Planned integration of MeVis' lung screening software for efficient
    interpretation of CT chest images in comprehensive lung screening
    solution of industrial customer

  - Product release at RSNA in November 2014, the world's most important
    annual meeting of American radiologists

  - Improved workflow, high diagnostic quality particularly and support of
    patient management systems particularly with higher caseloads such as
    in future national lung screening programs

  - Market potential especially in the US

  - First revenues expected in the first quarter 2015

Bremen, August 14, 2014 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4],
a leading provider of medical imaging software, announces, that they signed
a contract with an important industrial customer for use of the MeVis'
software for improving the early detection of lung cancer within lung
screenings.

Besides prostate, colon and breast cancer, lung cancer is today among the
four most common cancers. But since it is noticable relatively late by
symptoms and discomfort, an early diagnosis is of essential importance for
treatment and the prognosis of patients. Way back there have already been
discussions about the possibilities of early detection of lung cancer. And,
at least for the U.S., the introduction of appropriate screening programs
based on CT images are within reach since mid 2013. In national studies
(Early Lung Cancer Action Project - ELCAP and National Lung Screening Trial
- NLST) in the United States it has been verified that CT lung screening is
far superior in detection of lung cancer at an early stage compared to
normal radiography. And thus the responsible Expert Committee (USPSTF) has
issued a recommendation for a lung screening in December 2013. Accordingly,
a strong increase in lung CT images, which need to be diagnosed, is
expected. MeVis assumes that, as a result, there will be an increased
demand for solutions that simplify, shorten and improve the quality of this
this procedure. An introduction in Europe is also discussed.

MeVis' software, the world's first dedicated software for the efficient
diagnosis of images from CT lung screening, combined with a patient
management software from the industrial customer and a training solution
based on the MeVis Online Academy will be launched initially in the USA.
The timely launch is also possible because of the existing approval from
the FDA (U.S. Food & Drug Administration), the moment the software is
completed. Especially in areas with higher caseloads, such as lung
screening programs, the software solution offers important innovations to
improve the workflow and diagnostic quality. Besides an optimized
diagnostic workflow, the system includes one-click segmentation of
pulmonary nodules, the automatic integration of prior findings, an
integrated CAD (Computer-Aided Detection) system, software support for
patient management, and a state-of-the-art reporting according to current
guidelines (Lung-RADS of the American College of Radiology).

MeVis' already CE and FDA certified CAD software was developed in close
cooperation with the renowned Radboud University of Nijmegen and is a
reliable support for efficient diagnosis of high-resolution chest CT
images. The automatic identification of suspicious lung nodules by
validated CAD algorithms leads to clinically proven more reliable findings.

The online education & training portal on the basis of radiological case
collections offers customized web-based training opportunities for clinical
education and training of thorax radiologists and other healthcare
professionals in terms of lung cancer screening and workflow.

MeVis benefits from its many years of extensive experience in relation to
screening programs for the early detection of breast cancer. Thus the
world's first digital diagnostic system for mammography screening had also
been developed by MeVis in the past.

"Through our early decision to develop a dedicated software solution to
support lung cancer screenings, we are able to participate in this
atttractive growth market at a very early stage.", says Marcus Kirchhoff,
CEO of MeVis Medical Solutions AG.  "We are pleased to contribute to the
early detection and successful treatment of lung cancer.", says Marcus
Kirchhoff, CEO of MeVis Medical Solutions AG.

"We are very satisfied that we have already won a significant industrial
customer for this product.", adds Dr. Robert Hannemann, CFO. "We expect the
first revenues from this cooperation in the first quarter of 2015."



---------------------------------------------------------------------

14.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     MeVis Medical Solutions AG                             
             Caroline-Herschel-Str. 1                               
             28359 Bremen                                           
             Germany                                                
Phone:       +49 421 224 95 0                                       
Fax:         +49 421 224 95 999                                     
E-mail:      ir@mevis.de                                            
Internet:    http://www.mevis.de                                    
ISIN:        DE000A0LBFE4                                           
WKN:         A0LBFE                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
282402 14.08.2014